Tg Therapeutics (TGTX) Net Equity Issued and Repurchased (2011 - 2023)
Tg Therapeutics (TGTX) posted quarterly Net Equity Issued and Repurchased of -$1000.0 for Q4 2023, up 99.88% quarter-over-quarter from -$803000.0 in Q3 2023.
Powered by 
Analysis
Tg Therapeutics (TGTX) Net Equity Issued and Repurchased (2011 - 2023) Analysis & Trends
Tg Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at -$1000.0 for Q4 2023.
- In Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$1000.0; the TTM figure through Dec 2024 stood at -$804000.0 (down 104.9% YoY), while the FY2023 annual figure was $46.3 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q4 2023 stood at -$1000.0, up from -$803000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was -$1000.0 in Q4 2023, with the low at -$803000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Mar 31, 2014 | 17.22 Mn |
| Sep 30, 2013 | 37.65 Mn |
| Dec 31, 2011 | 9.79 Mn |
| Sep 30, 2011 | 30,115.00 |